Involvement of Adenosine A2a Receptor in Intraocular Pressure Decrease Induced by 2-(1-Octyn-1-yl)adenosine or 2-(6-Cyano-1-hexyn-1-yl)adenosine

DOI Web Site PubMed 参考文献22件
  • Konno Takashi
    Drug Research Section II, Fukushima Research Laboratories, Toa Eiyo Ltd.
  • Murakami Akira
    Drug Research Section I, Tokyo Research Laboratories, Toa Eiyo Ltd.
  • Uchibori Takehiro
    Drug Research Section II, Fukushima Research Laboratories, Toa Eiyo Ltd.
  • Nagai Akihiko
    Drug Research Section II, Fukushima Research Laboratories, Toa Eiyo Ltd.
  • Kogi Kentaro
    Drug Research Section II, Fukushima Research Laboratories, Toa Eiyo Ltd.
  • Nakahata Norimichi
    Department of Cellular Signaling and 21st Century COE Program, Graduate School of Pharmaceutical Sciences, Tohoku University

この論文をさがす

抄録

The aim of the present study is to clarify the mechanism for the decrease in intraocular pressure by 2-alkynyladenosine derivatives in rabbits. The receptor binding analysis revealed that 2-(1-octyn-1-yl)adenosine (2-O-Ado) and 2-(6-cyano-1-hexyn-1-yl)adenosine (2-CN-Ado) selectively bound to the A2a receptor with a high affinity. Ocular hypotensive responses to 2-O-Ado and 2-CN-Ado were inhibited by the adenosine A2a-receptor antagonist 1,3,7-trimethyl-8-(3-chlorostyryl)xanthine (CSC), but not by the adenosine A1-receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX) or the adenosine A2b-receptor antagonist alloxazine. In addition, 2-O-Ado and 2-CN-Ado caused an increase in outflow facility, which was inhibited by CSC, but not by DPCPX or alloxazine. Moreover, 2-O-Ado and 2-CN-Ado increased cAMP in the aqueous humor, and the 2-O-Ado-induced an increase in cAMP was inhibited by CSC. These results suggest that 2-O-Ado and 2-CN-Ado reduced intraocular pressure via an increase in outflow facility. The ocular hypotension may be mailnly mediated through the activation of adenosine A2a receptor, although a possible involvement of adenosine A1 receptor cannot be completely ruled out. 2-O-Ado and 2-CN-Ado are useful lead compounds for the treatment of glaucoma.<br>

収録刊行物

参考文献 (22)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ